Organization · Private Equity
Oberland Capital
Oberland Capital is a private investment firm established in 2013, specializing in flexible investment structures within the global healthcare sector. The firm manages over $3 billion in assets, focusing on customized financing solutions for its partners.
Overview
What Oberland Capital does
What Oberland Capital is
Oberland Capital is a private investment firm established in 2013, specializing in flexible investment structures within the global healthcare sector. The firm manages over $3 billion in assets, focusing on customized financing solutions for its partners.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Private Equity
- Founded
- Founded in 2013
- Approximate age
- About 13 years
- Structured capabilities
- Funder
- Last reviewed
- April 4, 2026
Official channels
Find Oberland Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Oberland Capital as a funder
Investment thesis
Oberland Capital is dedicated to funding innovation across the global healthcare industry, focusing on clinical-stage and commercial-stage companies.
Focus narrative
Oberland Capital invests primarily in the pharmaceutical, biotechnology, medical device, and diagnostics sectors. The firm employs a broad array of transaction structures, including royalty monetizations, royalty-backed securities, revenue interests, traditional debt, project-based structures, and hybrid structures. The target investment size ranges from $50 million to over $300 million, focusing on commercial-stage and near-commercial-stage healthcare products, while also considering earlier-stage opportunities.
Value beyond capital
Oberland Capital provides tailored investment structures and strategic support to enhance the growth and success of its portfolio companies in the healthcare sector.
Terms and economics
- Typical check
- $50,000,000–$300,000,000
Focus and fit
- Stages
- Series A · Series B · Series C · Growth Equity
- Sectors
- Biotech · Healthcare · Pharma Tech · Medical Devices · Diagnostics
- Regions
- Global · North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 16
- Recorded notable exits
- Impact Biomedicines
Portfolio context
Notable portfolio companies include ClearPoint Neuro, Biohaven, Verastem Oncology, BillionToOne, ImmunityBio, Humacyte, Helsinn, Zealand Pharma, Centessa Pharmaceuticals, Mirum Pharmaceuticals, Axogen, Esperion, NorthStar Medical Radioisotopes, Invitae, Impact Biomedicines, Agenus, and Oxford BioMedica.
Common questions
What to know about Oberland Capital
Upseed classifies Oberland Capital under the Private Equity organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 4, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.